At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 36 enrolled
Drug / intervention
Blinatumomabbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label, Multicenter, Exploratory Phase II Study to Evaluate the Efficacy, Safety, and Tolerability of the BiTE® Antibody Blinatumomab in Adult Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
In Brief
A Phase 2 clinical trial evaluating Blinatumomab for B-ALL. Completed, enrolled 36 participants across 9 sites.
Detailed Summary
The purpose of this study is to determine whether the bispecific T-cell engager blinatumomab is effective, safe and tolerable in the treatment of patients with relapsed/refractory B-precursor ALL.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsB-ALL
CountriesGermany
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedSep 2010
Enrollment StartOct 2010
Primary CompletionMar 2012
Study CompletionOct 2016
TodayJul 2026
First PostedSep 27, 2010
Enrollment StartOct 1, 2010
Primary CompletionMar 1, 2012
Study CompletionOct 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 15.8 years ago
Interventions
Blinatumomabbiological
Continuous intravenous infusion over four weeks per treatment cycle